Piramal Alternatives Funds Rs 110 Cr to Biodeal Pharma

Piramal Enterprises’ alternative investment arm, Piramal Alternatives, has made a strategic move by infusing Rs 110 crore into Biodeal Pharmaceuticals. This investment aims to propel Biodeal’s growth trajectory and solidify its position in the pharmaceutical industry.

Biodeal Gears Up for the Future with Infrastructure

Biodeal Pharmaceuticals, headquartered in Noida, India, is a key player in contract development and manufacturing (CDMO) services, specializing in nasal spray formulations. The capital infusion from Piramal Alternatives will be utilized for a multi-pronged growth strategy. Biodeal plans to enhance its existing infrastructure, upgrade its technological capabilities to stay ahead of the curve, and establish a dedicated nutraceuticals manufacturing facility. This strategic investment highlights Piramal Alternatives’ confidence in the burgeoning nutraceuticals market, a segment expected to witness significant growth in the coming years.

Industry Leaders Voice Optimism on the Investment

Piramal Alternatives’ CEO, Kalpesh Kikani, emphasized the promising outlook for the nasal spray market segment and Biodeal’s leadership role within it. He commended Biodeal’s commitment to meeting stringent global regulatory standards, a crucial factor in Piramal Alternatives’ decision to invest.

Anurag Kumar, Biodeal Pharmaceuticals’ Managing Director, expressed his conviction that the capital injection will significantly fuel the company’s growth. He outlined plans to leverage the funds to triple Biodeal’s production capacity, establish a new facility complying with USFDA (United States Food and Drug Administration) accreditations within 15 months, and expand the company’s market reach. This expansion will not only solidify Biodeal’s presence in existing markets but also open doors to new opportunities.

A Catalyst for Biodeal’s Continued Success

The strategic investment from Piramal Alternatives is poised to be a game-changer for Biodeal Pharmaceuticals. By focusing on infrastructure expansion, technological advancements, and entry into the nutraceuticals space, Biodeal is well-positioned for continued success in the dynamic pharmaceutical landscape. This investment not only benefits Biodeal but also underscores Piramal Alternatives’ commitment to supporting the growth of promising companies within the healthcare sector.

Recent Blog : Adani Gas, MG Motor Collaborate on EV Charging